Programme (Revised)
Tuesday 22 February 2022
12.30 - 13.00	Join meeting and networking in Virtual Coffee Bar
13.00 - 13.10	Welcome Toby Athersuch, Imperial College London, UK and Joint Organising Committee (RSC-BMCS, DMDG, DMG)
13.10 - 14.00	Keynote presentation: Metabolism of strained rings: tales of the unexpected Martin Hayes, AstraZeneca, SE
Flash poster presentations Session Chair: Toby Athersuch, Imperial College London, UK
14.00 - 14.05	Microfluidic hemodynamic model of blood-brain barrier on a chip to study drug transport into the brain Gaurav Gupta, University of Nottingham, UK
14.05 - 14.10	Exploring the application of enzyme-linked microfluidic reactors to the synthesis of oxidised and conjugated human drug metabolites Huw S Jones, University of Bradford, UK
14.10 - 14.15	Title to follow Speaker to follow
14.15 - 14.45	Bring-your-own coffee - exhibition, posters & networking
DMPK and Drug Discovery I – Chemistry and Mechanisms Session Chair: Mark Seymour, PharMAS Consulting, UK
14.45 - 15.25	The secret life of glucuronides Andrew Stachulski, University of Liverpool, UK
15.25 - 16.05	Preclinical DMPK applications of normothermic perfused whole porcine and cholestatic human livers Evita van der Steeg, TNO, The Netherlands
DMPK and Drug Discovery II – Application and Strategy Session Chair: Mark Seymour, PharMAS Consulting, UK
16.05 - 16.45	Is drug lipidation a new paradigm in DMPK? John Sanderson, Durham University, UK
16.45 - 17.25	Keynote presentation: Translational PKPD to guide drug discovery Piet H. van der Graaf, Senior Vice President, Certara & Professor of Systems Pharmacology Leiden University, The Netherlands
17.25	Close
Wednesday 23 February 2022
08.30 - 09.00	Join meeting and networking in Virtual Coffee Bar
Drug Discovery and Drug Safety Session Chair: Andrew Stachulski, University of Liverpool, UK
09.00 - 09.40	Acyl glucuronides in perspective Ian Wilson, Imperial College London, UK
09.40 - 10.20	The ADME and PKPD profile of an Ion Channel Blocker for a Hot Target Kevin Beaumont, AstraZeneca, Cambridge, UK
10.20 - 11.00	The Impact of Aldehyde Oxidase Mediated Metabolism in the Development of a Clinical Candidate, AWZ1066S, for the Treatment of Human Filariasis David Hong, University of Liverpool, UK
11.00 - 11.20	Bring-your-own coffee - exhibition, posters & networking
Analytical and Computational Advances in DMPK - Part 1 Session Chair: Dean Naisbit, University of Liverpool, UK
11.20 - 12.00	DILIsym Quantitative Systems Toxicology modelling – GSK experience Melanie Sakatis, GSK, UK
12.00 - 12.40	Characterization of T-cell responses exhibited to BACE inhibitor atabecestat and its metabolites in patients with drug liver injury Paul Thomson, University of Liverpool, UK
12.40 - 13.20	Optimising proteolysis targeting chimeras (PROTACs) for oral drug delivery: A drug metabolism and pharmacokinetics perspective Andy Pike, AstraZeneca Ltd, UK
13.20 - 14.20	Bring-your-own lunch - exhibition, posters & networking
Analytical and Computational Advances in DMPK - Part 2 Session Chair: Xiaoli Meng, University of Liverpool, UK
14.20 - 15.00	Use of liver spheroids in a pharmaceutical hepatic safety strategy Sophie Regan, AstraZeneca, UK
15.00 - 15.40	Development of PolyCYPs as part of a One-Stop Metabolite Strategy Julia Shanu-Wilson & Vincent Poon, Hypha Discovery Ltd, UK
15.40 - 16.20	Finding the metabolite needle in a matrix haystack James O’Neill, Charles River Laboratories, UK
16.20	Closing remarks Toby Athersuch, Imperial College London, UK and Joint Organising Committee (RSC-BMCS, DMDG, DMG)
16.30	Close of meeting